Percutaneous closure of patent ductus arteriosus: short term results

2013 ◽  
Vol 41 (4) ◽  
pp. 310-318
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Percutaneous Closure ◽  
Short Term ◽  
Patent Ductus

ASSOCIATION OF PATENT DUCTUS ARTERIOSUS SIZE WITH CLINICAL FEATURES AND SHORT-TERM OUTCOMES IN PRETERM INFANTS LESS THAN 34 WEEKS

2020 ◽  
Vol 07 (03) ◽  
pp. 105-108
Author(s):  
Chandrakala Bada Shekharappa ◽  
Edison Albert Balakrishnan Elizabeth ◽  
Bharathi Balachander
Keyword(s):  
Patent Ductus Arteriosus ◽  
Preterm Infants ◽  
Clinical Features ◽  
Ductus Arteriosus ◽  
Short Term ◽  
Patent Ductus

scholarly journals Hemólisis aguda post implante de Paraguas de Rashklind en Ductus Arterioso Persistente. Tratamiento Quirúrgico.

2013 ◽  
Vol 9 (3) ◽  
pp. 123
Author(s):  
Jesús Jacinto CUSTODIO LÓPEZ ◽  
Milvio RAMIREZ LÓPEZ ◽  
Rafael GUERRERO VARGAS
Keyword(s):  
Cardiopulmonary Bypass ◽  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Percutaneous Closure ◽  
Patent Ductus

We report a case of an acute mechanical haemolisis in a woman of 50 years old that ocurred after a percutaneous closure of a patent ductus arteriosus by a Rashkind double umbrella prosthesis.Surgical removal of the device using Cardiopulmonary bypass and ligation of the duct were required before haemolisis was abolished.

scholarly journals Multi-centre, randomised non-inferiority trial of early treatment versus expectant management of patent ductus arteriosus in preterm infants (the BeNeDuctus trial): statistical analysis plan

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Tim Hundscheid ◽  
Rogier Donders ◽  
Wes Onland ◽  
Elisabeth M. W. Kooi ◽  
Daniel C. Vijlbrief ◽  
...  
Keyword(s):  
Statistical Analysis ◽  
Patent Ductus Arteriosus ◽  
Preterm Infants ◽  
Pharmacological Treatment ◽  
Ductus Arteriosus ◽  
Expectant Management ◽  
The United States ◽  
Statistical Analysis Plan ◽  
Short Term ◽  
Patent Ductus

Abstract Background Controversy exists about the optimal management of a patent ductus arteriosus (PDA) in preterm infants. A persistent PDA is associated with neonatal mortality and morbidity, but causality remains unproven. Although both pharmacological and/or surgical treatment are effective in PDA closure, this has not resulted in an improved neonatal outcome. In most preterm infants, a PDA will eventually close spontaneously, hence PDA treatment potentially increases the risk of iatrogenic adverse effects. Therefore, expectant management is gaining interest, even in the absence of convincing evidence to support this strategy. Methods/design The BeNeDuctus trial is a multicentre, randomised, non-inferiority trial assessing early pharmacological treatment (24–72 h postnatal age) with ibuprofen versus expectant management of PDA in preterm infants in Europe. Preterm infants with a gestational age of less than 28 weeks and an echocardiographic-confirmed PDA with a transductal diameter of > 1.5 mm are randomly allocated to early pharmacological treatment with ibuprofen or expectant management after parental informed consent. The primary outcome measure is the composite outcome of mortality, and/or necrotizing enterocolitis Bell stage ≥ IIa, and/or bronchopulmonary dysplasia, all established at a postmenstrual age of 36 weeks. Secondary short-term outcomes are comorbidity and adverse events assessed during hospitalization and long-term neurodevelopmental outcome assessed at a corrected age of 2 years. This statistical analysis plan focusses on the short-term outcome and is written and submitted without knowledge of the data. Trial registration ClinicalTrials.gov NTR5479. Registered on October 19, 2015, with the Dutch Trial Registry, sponsored by the United States National Library of Medicine Clinicaltrials.gov NCT02884219 (registered May 2016) and the European Clinical Trials Database EudraCT 2017-001376-28.

Percutaneous Closure of the Patent Ductus Arteriosus in Very-Low-Weight Infants

NeoReviews ◽  
2020 ◽  
Vol 21 (7) ◽  
pp. e469-e478
Author(s):  
Danielle Scerbo ◽  
Clifford L. Cua ◽  
Brian K. Rivera ◽  
Laura C. Marzec ◽  
Charles V. Smith ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Percutaneous Closure ◽  
Low Weight ◽  
Patent Ductus

scholarly journals Amplatzer Piccolo Occluder clinical trial for percutaneous closure of the patent ductus arteriosus in patients ≥700 grams

2020 ◽  
Vol 96 (6) ◽  
pp. 1266-1276 ◽  
Author(s):  
Shyam K. Sathanandam ◽  
Dan Gutfinger ◽  
Laura O'Brien ◽  
Thomas J. Forbes ◽  
Matthew J. Gillespie ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Percutaneous Closure ◽  
Patent Ductus
Sign in / Sign up

Export Citation Format

Share Document